Noninvasive indicators predict advanced liver fibrosis in autoimmune hepatitis patients

Background Liver biopsy is the criterion standard for diagnosing liver fibrosis, but it is not widely used to monitor liver fibrosis because of the invasiveness, risk of complications, and sample errors. Therefore, it is necessary to involve other techniques to monitor liver fibrosis or cirrhosis during clinical practice. The objective was to explore noninvasive indicators to predict advanced liver fibrosis in autoimmune hepatitis (AIH) patients. Methods A total of 45 AIH patients and 47 healthy controls were recruited to this retrospective study. Complete blood count and liver function tests were performed for all subjects. AIH patients were divided into “no/minimal fibrosis” group and “advanced fibrosis” group based on liver biopsy. Results AIH patients demonstrated significantly higher monocytes, MCV, RDW‐CV, RDW‐SD, NLR, RDW‐CV/PLT, RDW‐SD/PLT, TBIL, DBIL, GLB, ALT, AST, GGT, ALP, and GPR and lower WBC, neutrophils, lymphocytes, RBC, HGB, HCT, LMR, TP, ALB, and AAR compared with healthy controls. Patients with advanced fibrosis showed remarkably higher RDW‐CV, RDW‐SD, RDW‐CV/PLT, RDW‐SD/PLT, AAR, and FIB‐4 and lower RBC, PLT, PCT, and ALB compared with the no/minimal fibrosis group. Logistic regression analysis showed that RDW‐SD/PLT was an independent risk factor for advanced fibrosis with an OR (95% CI) of 2.647 (1.383‐5.170). Receiver operating characteristic (ROC) analysis revealed that RDW‐SD, RDW‐CV/PLT, RDW‐SD/PLT, FIB‐4, and AAR had an area under the ROC curve (AUC) above 0.700 and RDW‐SD/PLT had the largest AUC of 0.785 with a cutoff value of 0.239. Conclusion RDW‐SD, RDW‐CV/PLT, RDW‐SD/PLT, FIB‐4, and AAR were excellent noninvasive biomarkers and RDW‐SD/PLT was an independent risk factor for predicting advanced fibrosis in AIH patients.